Kaplan–Meier analyses further confirmed that DLBCL patients with elevated CXCR5 and LAG‐3 expression exhibited significantly lower post‐treatment 5‐year PFS and OS compared to those with lower expression levels. The gene discussed is CXCR5; the disease is diffuse large B-cell lymphoma.